Drugs / ADENOVIRUS TYPE 26 ENCODING EBOLA VIRUS GLYCOPROTEIN
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Zabdeno | — | 2026-05-01 | europa.eu ↗ |
| Approved | EU (EMA) | Zabdeno | — | 2020-07-01 | europa.eu ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06126822 | Feb 2025 → Oct 2026 expected | Ebola hemorrhagic fever | Institute of Tropical Medicine, Belgium | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADENOVIRUS TYPE 26 ENCODING EBOLA VIRUS GLYCOPROTEIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068378 ↗ |
| Known as | Zabdeno | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06126822 ↗ |
| Route | Intramuscular | “single intramuscular Zabdeno® booster vaccine” NCT06126822 ↗ |